CandlesenseCandlesense
MRK•benzinga•

Merck Expects 2024 Adjusted EPS Of $7.72-$7.77 Compared To Prior Guidance Of $$7.94-$8.04 And Consensus Of $7.74, Outlook Reflects a Net Negative Impact of $0.24/Share Related to Business Development Transactions With Curon Biopharmaceutical and Daiichi S

Summary

No summary available.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on October 31, 2024 by benzinga

← Back to MRK News
    Merck Expects 2024 Adjusted EPS Of $7.72-$7.77 Compared To Prior Guidance Of $$7.94-$8.04 And Consensus Of $7.74, Outlook Reflects a Net Negative Impact of $0.24/Share Related to Business Development Transactions With Curon Biopharmaceutical and Daiichi S | MRK Stock News | Candlesense